Evidence map›Paper›PMID 41865207›Full record

ArticleAnnals of surgical oncology2026

Salvage Metastasectomy After Adoptive Cell Transfer for Melanoma: Long-Term Updates.

Aaron J Dinerman, Alexandra M Gustafson, Kyle J Hitscherich, Donald E White, Sri Krishna, David S Schrump, Chuong D Hoang, Jonathan M Hernandez, Jared J Gartner, Paul F Robbins and 5 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Annals of surgical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Aaron J DinermanSurgery Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
Alexandra M GustafsonSurgery Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
Kyle J HitscherichSurgery Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
Donald E WhiteSurgery Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
Sri KrishnaSurgery Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
David S SchrumpThoracic Surgery Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
Chuong D HoangThoracic Surgery Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
Jonathan M HernandezSurgical Oncology Program, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
Jared J GartnerSurgery Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
Paul F RobbinsSurgery Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
Mei Li KwongSurgery Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
Stephanie L GoffSurgery Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
James C YangSurgery Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
Steven A RosenbergSurgery Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
Nicholas D KlemenSurgery Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA. nicholas.klemen@gmail.com.ORCID http://orcid.org/0000-0003-1353-539X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAdoptive cell transfer (ACT) can mediate durable regression in patients with metastatic melanoma, and some patients with initial response may progress, requiring salvage therapy.

methodsWe report updated follow-up on a retrospective review of patients with metastatic melanoma receiving ACT at a single institution from 2000 to 2022. We identified patients with objective response (RECIST 1.0) or stable disease for at least 6 months (SD6) before experiencing oligoprogression in up to three extracranial sites managed with surgery. The primary outcomes were progression-free survival (PFS) and overall survival (OS) after surgery. We also performed an exploratory analysis for genomic mechanisms of tumor escape.

resultsIn total, 138 patients with metastatic melanoma treated with ACT had an objective response or SD6 before experiencing disease progression. Of these, 30 (21%) had extracranial oligoprogression managed with metastasectomy. With a median follow-up of 132 months (range 5-248), median OS was not reached and median PFS was 10.5 months. Ten-year OS was 54.7% and plateaued after 6 years. Four patients with pre- and post-ACT tumor sequencing demonstrated significant mutational evolution, with one patient experiencing loss of two major histocompatibility complex class I-restricted neoantigens recognized by T cells in the original infusion product.

conclusionsOf patients experiencing oligoprogression after initial response to ACT (complete response, partial response, or SD6), 27% derived durable disease control after surgical management, confirming a potentially viable salvage option for "local" failures following ACT that may not portend systemic failure. Additional factors related to ACT response and oligoprogression that may guide patient selection for salvage metastasectomy remain undefined.

Indexed as

Adoptive TransferImmunotherapy, AdoptiveMelanomaMetastasectomySalvage TherapySkin NeoplasmsAdultFemaleFollow-Up StudiesHumansMaleMiddle AgedPrognosisRetrospective StudiesSurvival Rate

Identifiers

PMID41865207
PMCPMC13452880

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.